Advanced

The Better Diabetes Diagnosis (BDD) study – A review of a nationwide prospective cohort study in Sweden

Persson, M.; Becker, C. LU ; Elding Larsson, H. LU ; Lernmark, LU ; Forsander, G.; Ivarsson, S. A. LU ; Ludvigsson, J.; Samuelsson, U.; Marcus, C. and Carlsson, A. LU (2018) In Diabetes Research and Clinical Practice 140. p.236-244
Abstract

The incidence of type 1 diabetes (T1D) in Sweden is one of the highest in the world. However, the possibility of other types of diabetes must also be considered. In addition, individuals with T1D constitute a heterogeneous group. A precise classification of diabetes is a prerequisite for optimal outcome. For precise classification, knowledge on the distribution of genetic factors, biochemical markers and clinical features in individuals with new onset of diabetes is needed. The Better Diabetes Diagnosis (BDD), is a nationwide study in Sweden with the primary aim to facilitate a more precise classification and diagnosis of diabetes in order to enable the most adequate treatment for each patient. Secondary aims include identification of... (More)

The incidence of type 1 diabetes (T1D) in Sweden is one of the highest in the world. However, the possibility of other types of diabetes must also be considered. In addition, individuals with T1D constitute a heterogeneous group. A precise classification of diabetes is a prerequisite for optimal outcome. For precise classification, knowledge on the distribution of genetic factors, biochemical markers and clinical features in individuals with new onset of diabetes is needed. The Better Diabetes Diagnosis (BDD), is a nationwide study in Sweden with the primary aim to facilitate a more precise classification and diagnosis of diabetes in order to enable the most adequate treatment for each patient. Secondary aims include identification of risk factors for diabetes-related co-morbidities. Since 2005, data on almost all children and adolescents with newly diagnosed diabetes in Sweden are prospectively collected and including heredity of diabetes, clinical symptoms, levels of C peptide, genetic analyses and detection of autoantibodies. Since 2011, analyses of HLA profile, autoantibodies and C peptide levels are part of clinical routine in Sweden for all pediatric patients with suspected diagnosis of diabetes. In this review, we present the methods and main results of the BDD study so far and discuss future aspects.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetes Research and Clinical Practice
volume
140
pages
9 pages
publisher
Elsevier
external identifiers
  • scopus:85045259601
ISSN
0168-8227
DOI
10.1016/j.diabres.2018.03.057
language
English
LU publication?
yes
id
86e7c358-d228-4941-aba0-5c074107a50c
date added to LUP
2018-04-23 13:13:33
date last changed
2019-04-10 04:07:02
@article{86e7c358-d228-4941-aba0-5c074107a50c,
  abstract     = {<p>The incidence of type 1 diabetes (T1D) in Sweden is one of the highest in the world. However, the possibility of other types of diabetes must also be considered. In addition, individuals with T1D constitute a heterogeneous group. A precise classification of diabetes is a prerequisite for optimal outcome. For precise classification, knowledge on the distribution of genetic factors, biochemical markers and clinical features in individuals with new onset of diabetes is needed. The Better Diabetes Diagnosis (BDD), is a nationwide study in Sweden with the primary aim to facilitate a more precise classification and diagnosis of diabetes in order to enable the most adequate treatment for each patient. Secondary aims include identification of risk factors for diabetes-related co-morbidities. Since 2005, data on almost all children and adolescents with newly diagnosed diabetes in Sweden are prospectively collected and including heredity of diabetes, clinical symptoms, levels of C peptide, genetic analyses and detection of autoantibodies. Since 2011, analyses of HLA profile, autoantibodies and C peptide levels are part of clinical routine in Sweden for all pediatric patients with suspected diagnosis of diabetes. In this review, we present the methods and main results of the BDD study so far and discuss future aspects.</p>},
  author       = {Persson, M. and Becker, C. and Elding Larsson, H. and Lernmark,  and Forsander, G. and Ivarsson, S. A. and Ludvigsson, J. and Samuelsson, U. and Marcus, C. and Carlsson, A.},
  issn         = {0168-8227},
  language     = {eng},
  month        = {06},
  pages        = {236--244},
  publisher    = {Elsevier},
  series       = {Diabetes Research and Clinical Practice},
  title        = {The Better Diabetes Diagnosis (BDD) study – A review of a nationwide prospective cohort study in Sweden},
  url          = {http://dx.doi.org/10.1016/j.diabres.2018.03.057},
  volume       = {140},
  year         = {2018},
}